Pfizer, Anumana Team Up to Develop AI Algorithm for Cardiac Amyloidosis Detection

Anumana has entered into a multiyear partnership with Pfizer to develop an AI-based tool for the early detection of cardiac amyloidosis.

Cardiac amyloidosis is caused by the buildup of abnormal proteins in the heart, which hampers its ability to pump blood. The disease can lead to heart failure, and outcomes depend on the type of amyloidosis and how early it's found.

Under the agreement, Anumana will research and pursue FDA De Novo classification for an algorithm that could find signals within electrocardiograms (ECGs) that hint at the condition. The partners also aim to gain regulatory clearance in Europe and Japan. 

Anumana, launched in 2021, is a joint venture between EHR data company nference and the Mayo Clinic. The joint venture has licensed Mayo Clinic ECG algorithms for low ejection fraction, pulmonary hypertension and hyperkalemia, all of which have received FDA Breakthrough Device Designation.

Dr. Paul Friedman, chair of the department of cardiovascular medicine at Mayo Clinic and chair of Anumana's Mayo Clinic Board of Advisors, said in a statement, “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease. This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.”

Join the HealthXL Webinar on ‘Retail Healthcare: Current and Future Opportunities for Digital Health’ on 26th January. Click here to Request to Join. 

Click here to read the original news story.